NCT Number: NCT00195598
Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder
The purpose of this pilot study is to evaluate the improvement in social function following therapy with venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine. An additional purpose of this pilot study is to obtain the tolerability of using venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine.
Looking for future studies?
Notify MeKey information
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Jundiaí, São Paulo, Brazil
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Meet DSM IV criteria for Panic Disorder (with or without agoraphobia) for at least 3 months before study day 1.
- Have a minimum of 8 full-symptom panic attacks during the 4 weeks before the screening visit.
- Provide a written informed consent
Exclusion criteria
- Treatment with Venlafaxine within 6 months of study day 1, as well Paroxetine
- Known hypersensitivity to Venlafaxine or related compounds as well to Paroxetine.
- Psychopharmacologic drugs within 14 days of study day 1
Treatment and study plan
paroxetine
DrugPrimary outcomes
-
To evaluate the improvement of social function following therapy with Venlafaxine extended release (XR)in the Treatment of Panic Disorder in comparison to Paroxetine.
Secondary outcomes
-
Obtain the tolerability of using Venlafaxine extended release (XR) in the treatment of Panic Disorder in comparison to Paroxetine.
Sponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
Pilot Study of Venlafaxine Extended Release (XR) in the Treatment of Panic Disorder (PD) in Comparison to Paroxetine.
Important dates
- Study start
- 2005
- Primary completion
- 2006
- Study completion
- 2006
- First posted
- Sep 19, 2005
- Registry last updated
- Apr 2, 2010
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Effectiveness of Cognitive Behavioral Therapy With Panic Control Treatment for Adolescents With Panic Disorder
NCT00705380
Anxiety Disorders, Mental Disorders
Boston, Massachusetts, United States
View Trial DetailsEffectiveness of Intensive Cognitive Behavioral Therapy in Treating Adolescent Panic Disorder and Agoraphobia
NCT00576719
Agoraphobia, Anxiety Disorders
Boston, Massachusetts, United States
View Trial Detailsα-N-acetylgalactosaminidase Levels in Panic Disorder
NCT07424911
Anxiety Disorders, Mental Disorders
Elâzığ, Turkey (Türkiye)
View Trial DetailsInvestigation of Pathogenic Gut Microbiota Patterns in Anxiety, Depression and Panic Disorders
NCT07268729
Anxiety, Anxiety Disorders
Mississauga, Ontario, Canada
View Trial Details